Literature DB >> 8773167

Adverse effects of the angiotensin-converting enzyme inhibitors.

C P Alderman1.   

Abstract

OBJECTIVE: To review current literature relating to the adverse effects of the angiotensin-converting enzyme (ACE) inhibitors. DATA SOURCES: Online drug information sources, including MEDLINE (1966-November 1994), Iowa Drug Information Service, and the Australian Medical Index (AMI), were used to identify relevant literature, including reviews. DATA EXTRACTION: Data were extracted from studies described in the English-language literature dealing with the adverse effects of ACE inhibitors. Comprehensive reviews and relevant case reports also were included. DATA SYNTHESIS: Important adverse effects of ACE inhibitors include first-dose hypotension, renal dysfunction, hyperkalemia, and cough. Less common adverse effects include angioedema, hepatotoxicity. Skin rashes, and dysgeusia. ACE inhibitors also are associated with adverse fetal effects; thus, this class of drugs in contraindicated in pregnancy. Some adverse effects of ACE inhibitors are predictable on the basis of the fundamental pharmacology of this class of drugs. However, other effects are idiosyncratic in nature, although these reactions are generally much less common.
CONCLUSIONS: Attention to the principles of risk assessment, risk immunization, and patient monitoring are important when ACE inhibitor therapy is used for any indication. Provided these steps are taken. ACE inhibitors are generally a safe and effective class of drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8773167     DOI: 10.1177/106002809603000110

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  14 in total

Review 1.  Joining the DoTS: new approach to classifying adverse drug reactions.

Authors:  J K Aronson; R E Ferner
Journal:  BMJ       Date:  2003-11-22

Review 2.  Clarification of terminology in drug safety.

Authors:  Jeffrey K Aronson; Robin E Ferner
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Severe migratory Angioedema due to ACE inhibitors use.

Authors:  G Peltekis; D Palaskas; M Samanidou; A Fragakis; K Alexopoulos; A Kotsani; I Vogiatzis; E Kyrmizakis
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

4.  [ACE inhibitor-induced angioedema in the head and neck region. A matter of time?].

Authors:  M Bas; G Kojda; H Bier; T K Hoffmann
Journal:  HNO       Date:  2004-10       Impact factor: 1.284

Review 5.  Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure.

Authors:  R Davis; A Coukell; D McTavish
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

6.  [Elevated liver enzymes in rheumatoid arthritis : differential diagnostic considerations based on a case report].

Authors:  U Hartmann; S Schmitt; M Reuss-Borst
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

Review 7.  Angiotensin II in inflammation, immunity and rheumatoid arthritis.

Authors:  Y Chang; W Wei
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

Review 8.  Delapril plus indapamide: a review of the combination in the treatment of hypertension.

Authors:  Luca Cavalieri; Giovanni Cremonesi
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

9.  Dose-Related Antihypertensive Properties and the Corresponding Mechanisms of a Chicken Foot Hydrolysate in Hypertensive Rats.

Authors:  Anna Mas-Capdevila; Zara Pons; Amaya Aleixandre; Francisca I Bravo; Begoña Muguerza
Journal:  Nutrients       Date:  2018-09-12       Impact factor: 5.717

10.  Bioanalytical Assessment of Plasma Concentrations of Angiotensin-Converting Enzyme II Inhibitors and Angiotensin Receptor Blockers: A Pilot Study Among Patients Hospitalized With Acute Heart Failure.

Authors:  Candace D McNaughton; Sean P Collins; JoAnn Lindenfeld; Ryan Morrison; John Scott Daniels; Thomas J Wang
Journal:  Am J Ther       Date:  2020 Jul/Aug       Impact factor: 3.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.